Oramed Pharmaceuticals sell StockNews.com
Start price
04.01.25
/
50%
€2.33
Target price
04.01.26
-
Performance (%)
7.89%
End price
05.01.26
€2.52
Summary
This prediction ended on 05.01.26 with a price of €2.52. The SELL prediction by StockNews_com shows the price for Oramed Pharmaceuticals slightly increased by 7.89% during the runtime of the prediction. StockNews_com has a follow-up prediction for Oramed Pharmaceuticals where he still thinks Oramed Pharmaceuticals is a Sell. StockNews_com has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Oramed Pharmaceuticals | 6.722% | 6.722% | 9.708% |
| iShares Core DAX® | 2.462% | 4.579% | 23.150% |
| iShares Nasdaq 100 | 1.237% | -0.442% | 7.600% |
| iShares Nikkei 225® | 2.933% | 1.229% | 16.068% |
| iShares S&P 500 | 0.975% | 0.565% | 4.794% |
Comments by StockNews_com for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ORMP provided by MarketBeat
In the thread Trading Oramed Pharmaceuticals
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten